Baseline characteristics of the complete discovery cohort of 408 patients with AML
| Characteristic . | Full cohort . | ||||||
|---|---|---|---|---|---|---|---|
| Age, median (range), y | 60 (18-84) | ||||||
| Sex, n (%) | |||||||
| Female | 168 (41.2) | ||||||
| Male | 240 (58.8) | ||||||
| AML type, n (%) | |||||||
| De novo∗ | 194 (47.5) | ||||||
| AML-MRC | 158 (38.7) | ||||||
| De novo AML with MRC cytogenetics | 50 (31.6) | ||||||
| AML with antecedent MDS or MDS/MPN | 108 (68.4) | ||||||
| Therapy-related AML | 38 (9.3) | ||||||
| Missing | 18 (4.4) | ||||||
| WBC, median (range), 109/L | 10.9 (0.2-499.7) | ||||||
| LDH, median (range), U/L | 440 (130-6161) | ||||||
| Hemoglobin, median (range), g/dL | 8.7 (2.9-15.5) | ||||||
| Platelet count, median (range), 109/L | 64 (3-637) | ||||||
| Characteristic . | Full cohort . | ||||||
|---|---|---|---|---|---|---|---|
| Age, median (range), y | 60 (18-84) | ||||||
| Sex, n (%) | |||||||
| Female | 168 (41.2) | ||||||
| Male | 240 (58.8) | ||||||
| AML type, n (%) | |||||||
| De novo∗ | 194 (47.5) | ||||||
| AML-MRC | 158 (38.7) | ||||||
| De novo AML with MRC cytogenetics | 50 (31.6) | ||||||
| AML with antecedent MDS or MDS/MPN | 108 (68.4) | ||||||
| Therapy-related AML | 38 (9.3) | ||||||
| Missing | 18 (4.4) | ||||||
| WBC, median (range), 109/L | 10.9 (0.2-499.7) | ||||||
| LDH, median (range), U/L | 440 (130-6161) | ||||||
| Hemoglobin, median (range), g/dL | 8.7 (2.9-15.5) | ||||||
| Platelet count, median (range), 109/L | 64 (3-637) | ||||||
| . | Present/mutated . | Absent/wild type . | Missing . | ||||
|---|---|---|---|---|---|---|---|
| Cytogenetics, n (%) | |||||||
| t(8;21) | 8 (2.0) | 384 (94.1) | 16 (3.9) | ||||
| inv(16)/t(16;16) | 16 (3.9) | 376 (92.2) | 16 (3.9) | ||||
| Normal karyotype | 203 (49.8) | 188 (46.1) | 17 (4.2) | ||||
| t(9;11) | 6 (1.5) | 389 (95.3) | 13 (3.2) | ||||
| t(6;9) | 4 (1.0) | 387 (94.9) | 17 (4.2) | ||||
| t(9;22) | 2 (0.5) | 390 (95.6) | 16 (3.9) | ||||
| t(v;11q23) | 11 (2.7) | 385 (94.4) | 12 (2.9) | ||||
| inv(3)/t(3;3) | 13 (3.2) | 382 (93.6) | 13 (3.2) | ||||
| −5/del(5q) | 38 (9.3) | 355 (87.0) | 15 (3.7) | ||||
| −7 | 28 (6.9) | 358 (87.7) | 22 (5.4) | ||||
| abn(17p) | 28 (6.9) | 350 (85.8) | 30 (7.4) | ||||
| Complex karyotype | 63 (15.4) | 321 (78.7) | 24 (5.9) | ||||
| Monosomal karyotype | 55 (13.5) | 322 (78.9) | 31 (7.6) | ||||
| Other abnormalities | 56 (13.7) | 328 (80.4) | 24 (5.9) | ||||
| MRC cytogenetics | 102 (25.0) | 278 (68.1) | 28 (6.9) | ||||
| FLT3-ITD mutation, n (%) | 80 (19.6) | 320 (78.4) | 8 (2.0) | ||||
| FLT3-TKD mutation, n (%) | 10 (2.5) | 152 (37.3) | 246 (60.3) | ||||
| NPM1 mutation, n (%) | 113 (27.7) | 290 (71.1) | 5 (1.2) | ||||
| ELN 2017 favorable risk, n (%) | 100 (24.5) | 202 (49.5) | 106 (26.0) | ||||
| Mut/wt | Mut/mut | Wt/wt | Wt/mut | Missing | |||
| NPM1/FLT3-ITD, n (%) | 67 (16.4) | 45 (11.0) | 253 (62.0) | 35 (8.6) | 8 (2.0) | ||
| . | Present/mutated . | Absent/wild type . | Missing . | ||||
|---|---|---|---|---|---|---|---|
| Cytogenetics, n (%) | |||||||
| t(8;21) | 8 (2.0) | 384 (94.1) | 16 (3.9) | ||||
| inv(16)/t(16;16) | 16 (3.9) | 376 (92.2) | 16 (3.9) | ||||
| Normal karyotype | 203 (49.8) | 188 (46.1) | 17 (4.2) | ||||
| t(9;11) | 6 (1.5) | 389 (95.3) | 13 (3.2) | ||||
| t(6;9) | 4 (1.0) | 387 (94.9) | 17 (4.2) | ||||
| t(9;22) | 2 (0.5) | 390 (95.6) | 16 (3.9) | ||||
| t(v;11q23) | 11 (2.7) | 385 (94.4) | 12 (2.9) | ||||
| inv(3)/t(3;3) | 13 (3.2) | 382 (93.6) | 13 (3.2) | ||||
| −5/del(5q) | 38 (9.3) | 355 (87.0) | 15 (3.7) | ||||
| −7 | 28 (6.9) | 358 (87.7) | 22 (5.4) | ||||
| abn(17p) | 28 (6.9) | 350 (85.8) | 30 (7.4) | ||||
| Complex karyotype | 63 (15.4) | 321 (78.7) | 24 (5.9) | ||||
| Monosomal karyotype | 55 (13.5) | 322 (78.9) | 31 (7.6) | ||||
| Other abnormalities | 56 (13.7) | 328 (80.4) | 24 (5.9) | ||||
| MRC cytogenetics | 102 (25.0) | 278 (68.1) | 28 (6.9) | ||||
| FLT3-ITD mutation, n (%) | 80 (19.6) | 320 (78.4) | 8 (2.0) | ||||
| FLT3-TKD mutation, n (%) | 10 (2.5) | 152 (37.3) | 246 (60.3) | ||||
| NPM1 mutation, n (%) | 113 (27.7) | 290 (71.1) | 5 (1.2) | ||||
| ELN 2017 favorable risk, n (%) | 100 (24.5) | 202 (49.5) | 106 (26.0) | ||||
| Mut/wt | Mut/mut | Wt/wt | Wt/mut | Missing | |||
| NPM1/FLT3-ITD, n (%) | 67 (16.4) | 45 (11.0) | 253 (62.0) | 35 (8.6) | 8 (2.0) | ||
ELN, Euopean LeukemiaNet; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MRC, myelodysplasia-related changes; Mut, mutated; WBC, white blood cell count; wt, wild type.
Excludes AML with MRC cytogenetics.